We presented the results on the efficacy of RCI001 in dry eye disease.
The drug demonstrated superior efficacy in comparison with existing drugs, generating strong expectations for its potential success.
RudaCure is currently proceeding with GMP production of the drug and is targeting FDA clinical trial entry in 2023.